Carfilzomib

Generic Name: Carfilzomib

Brand Names: Kyprolis

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₇N_₅O_₇

CAS Number: 868540-17-4

Unique Ingredient Identifier: 72X6E3J5AR

Background: Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.

Indication: Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Associated Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical Trials

A Study of Daratumumab

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Pomalidomide

First Posted Date: 2022-06-29

Last Posted Date: 2025-04-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 500

Registration Number: NCT05438043

Locations: 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸
Barnes-jewish Hospital, Saint Louis, Missouri, United States
🇧🇪
ZNA Stuivenberg, Antwerpen, Belgium

and more 69 locations

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Iberdomide
Drug: Daratumumab
Drug: Dexamethasone
Drug: Carfilzomib

First Posted Date: 2022-06-28

Last Posted Date: 2025-04-16

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 80

Registration Number: NCT05434689

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Ohio State University Medical College, Columbus, Ohio, United States

and more 3 locations

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Iberdomide
Drug: Oral Dexamethasone

First Posted Date: 2022-01-20

Last Posted Date: 2025-05-21

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 66

Registration Number: NCT05199311

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Linvoseltamab
Drug: Nirogacestat
Drug: Isatuximab
Drug: Daratumumab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Pomalidomide
Drug: Fianlimab
Drug: Cemiplimab
Drug: Bortezomib

First Posted Date: 2021-11-30

Last Posted Date: 2025-03-07

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 317

Registration Number: NCT05137054

Locations: 🇪🇸
Hospital Clínico Universitario de Santiago, Santiago, A Coruña, Spain
🇺🇸
Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 35 locations

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

Phase 1

Recruiting

Conditions: Relapsed Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2021-09-29

Last Posted Date: 2022-09-08

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 60

Registration Number: NCT05060627

Locations: 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸
Hospital Germans Trias i Pujol (ICO BADALONA), Badalona, Spain
🇪🇸
Hospital Clinic, Barcelona, Spain

and more 12 locations

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Talquetamab
Drug: Carfilzomib
Drug: Pomalidomide
Drug: Daratumumab SC
Drug: Lenalidomide

First Posted Date: 2021-09-20

Last Posted Date: 2025-05-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 166

Registration Number: NCT05050097

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 28 locations

Carfilzomib and Belatacept for Desensitization

Phase 1

Recruiting

Conditions: Highly Sensitized Prospective Kidney Transplant Recipients

Interventions: Biological: carfilzomib
Biological: belatacept
Procedure: Bone marrow aspiration

First Posted Date: 2021-08-24

Last Posted Date: 2025-02-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 15

Registration Number: NCT05017545

Locations: 🇺🇸
Duke Transplant Center, Duke University Medical Center, Durham, North Carolina, United States

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Phase 1

Recruiting

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Sonrotoclax
Drug: Dexamethasone
Drug: Carfilzomib
Drug: Daratumumab
Drug: Pomalidomide

First Posted Date: 2021-07-22

Last Posted Date: 2025-05-22

Lead Sponsor: BeiGene

Target Recruit Count: 167

Registration Number: NCT04973605

Locations: 🇺🇸
University of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
City of Hope At Irvine Lennar, Irvine, California, United States

and more 85 locations